Latest news

Hide mandatory notifications of trade

Proposal from the Nomination Committee to the Annual General Meeting 22 April 2016

(Oslo, Norway, 19 April 2016) With reference to announcement of 31 March 2016, the Nomination Committee of Bionor has issued the attached statement regarding election of Board of Directors and Nomination Committee members.

The Annual General Meeting 2016 of Bionor Pharma ASA will be held on Friday 22 April 2016 at 12:00 hours at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway, “Møterom 4”.

All relevant documents can be found on

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Further information
Cecilie Grue, Director Legal Affairs, +47 99162486,
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03,

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by significantly reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at

Proposal from Nomination Committee April 2016 (PDF)